Hypera's planned buyout of 12 medicine brands from Sanofi Medley Farmacêutica has been declared "complex" by the Brazilian competition authority and will require an in-depth analysis because of what the agency deemed high concentration levels in certain markets.They include stimulant laxatives and prescription nasal decongestants."During the market test, several competitors and clients